248.00p-11.00 (-4.25%)06 Mar 2025, 16:35
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Hutchmed (China) Limited Fundamentals

Company NameHutchmed (China) LimitedLast Updated2025-03-06
IndustryDrug Manufacturers - Specialty & GenericSectorHealthcare
Shares in Issue854.681 mMarket Cap£2.12 bn
PE Ratio30.22Dividend per Share0
Dividend Yield0Dividend Cover0
EPS$0.12EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.0651Debt Equity Ratio0.0752
Asset Equity Ratio1.6766Cash Equity Ratio1.0671
Quick Ratio2.6610Current Ratio2.81
Price To Book Value3.8256ROCE0

Hutchmed (China) Limited Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Hutchmed (China) Limited Company Financials

Assets20232022
Tangible Assets$104.39 m$84.67 m
Intangible Assets00
Investments$48.41 m$73.78 m
Total Fixed Assets$182.93 m$189.56 m
Stocks$50.26 m$56.69 m
Debtors$149.91 m$127.17 m
Cash & Equivalents$886.34 m$631.00 m
Other Assets00
Total Assets$1.28 bn$1.03 bn
Liabilities20232022
Creditors within 1 year$403.03 m$353.90 m
Creditors after 1 year$133.36 m$38.67 m
Other Liabilities00
Total Liabilities$536.39 m$392.57 m
Net assets$743.39 m$636.87 m
Equity20232022
Called up share capital$87.13 m$86.48 m
Share Premium$1.52 bn$1.50 bn
Profit / Loss$58.31 m-$410.42 m
Other Equity$730.54 m$610.37 m
Preference & Minorities$12.85 m$26.50 m
Total Capital Employed$743.39 m$636.87 m
Ratios20232022
Debt Ratio$0.07$0.04
Debt-to-Equity$0.07$0.04
Assets / Equity1.67661.6766
Cash / Equity1.06711.0671
EPS$0.13-$0.43
Cash Flow20232022
Cash from operating activities$219.26 m-$268.60 m
Cashflow before financing$267.92 m-$351.36 m
Increase in Cash-$23.22 m-$54.77 m
Income20232022
Turnover$838.00 m$426.41 m
Cost of sales$384.45 m$311.10 m
Gross Profit$453.55 m$115.31 m
Operating Profit00
Pre-Tax profit$58.31 m-$410.42 m

Hutchmed (China) Limited Company Background

SectorHealthcare
ActivitiesHUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Latest Interim Date31 Jul 2024
Latest Fiscal Year End Date19 Mar 2025

Hutchmed (China) Limited Directors

AppointedNamePosition
2024-10-21Mr. Graeme Allan JackNon-Executive Director
2024-10-21Mr. Dan EldarNon-Executive Director,Chairman
2024-04-08Ms. Edith ShihNon-Executive Director,Company Secretary
2024-10-21Mr. Paul Rutherford CarterNon-Executive Director,Senior Independent Director
2017-02-01Mr. Christopher John NashDirector
2024-05-17Mr. Chi Keung Simon To Executive Director,Chairman
2022-03-03Mr. Christian HoggExecutive Director,Chief Executive Officer
2017-03-01Mr. Michael William Davis Howell Director
2017-02-01Professor Christopher Huang Non-Executive Director
2024-03-05Mr. Johnny Cheng Chig FUNGExecutive Director,Chief Financial Officer
2023-05-12Dr. Karen Jean Ferrante, M.D.Non-Executive Director
2024-08-06Dr. Weiguo SuExecutive Director,Chief Executive Officer and Chief Scientific Officer
2024-10-21Professor Shu Kam Tony MokNon-Executive Director
2024-05-08Dr. Renu BhatiaNon-Executive Director

Hutchmed (China) Limited Contact Details

Company NameHUTCHMED (China) Ltd
AddressUgland House, P.O. Box 309, Grand Cayman, KY1-1104
Telephone+852 21281188
Websitehttps://www.hutch-med.com

Hutchmed (China) Limited Advisors

Financial PR AdviserBMC Communications
Phone+1 646 513-3125
Financial PR AdviserThe Trout Group
Phone+86 15821996861
Fax+86 16463782901
RegistrarComputershare Investor Services Ltd
Phone+44 8707074040
Fax+44 3708735851
AuditorPricewaterhouseCoopers
Phone+852 22898888
Fax+852 28109888
StockbrokerPanmure Gordon (UK) Ltd
Phone+44 2078862500
StockbrokerUBS Limited
Phone+44 2075678000
SolicitorDLA Piper LLP
Phone+44 8700111111
Fax+44 2077966666
Financial PR AdviserCitigate Dewe Rogerson
Phone+44 2076389571
Nominated AdviserPanmure Gordon (UK) Ltd
Phone+44 2078862500